neuroendocrine tumors

Summary

Summary: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.

Top Publications

  1. pmc Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
  2. ncbi One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
  3. ncbi Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Service Inter Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hopital Beaujon, Clichy, France
    N Engl J Med 364:501-13. 2011
  4. pmc DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 331:1199-203. 2011
  5. ncbi Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Anja Rinke
    Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Germany
    J Clin Oncol 27:4656-63. 2009
  6. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
  7. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
  8. ncbi The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems
    David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Pancreas 39:707-12. 2010
  9. pmc TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
    G Rindi
    Dipartimento di Patologia e, Medicina di Laboratorio, Sezione di Anatomia Patologica, Universita di Parma, Via Gramsci, 14, 43100, Parma, Italy, and Department of Internal Medicine, Royal Free Hospital, London, UK
    Virchows Arch 449:395-401. 2006
  10. ncbi Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors
    Alexander S Ho
    Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, Saint Louis, MO 63110, USA
    AJR Am J Roentgenol 188:1201-7. 2007

Detail Information

Publications298 found, 100 shown here

  1. pmc Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
    ..oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.
  2. ncbi One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
    PURPOSE Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones...
  3. ncbi Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Service Inter Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hopital Beaujon, Clichy, France
    N Engl J Med 364:501-13. 2011
    The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
  4. pmc DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 331:1199-203. 2011
    Pancreatic neuroendocrine tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia...
  5. ncbi Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Anja Rinke
    Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Germany
    J Clin Oncol 27:4656-63. 2009
    Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs)...
  6. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
    Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years...
  7. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
    Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors.
  8. ncbi The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems
    David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Pancreas 39:707-12. 2010
    b>Neuroendocrine tumors (NETs) arise in most organs of the body and share many common pathologic features...
  9. pmc TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
    G Rindi
    Dipartimento di Patologia e, Medicina di Laboratorio, Sezione di Anatomia Patologica, Universita di Parma, Via Gramsci, 14, 43100, Parma, Italy, and Department of Internal Medicine, Royal Free Hospital, London, UK
    Virchows Arch 449:395-401. 2006
    ..and was based on the recently published ENETS guidelines on the diagnosis and treatment of digestive neuroendocrine tumors (NET)...
  10. ncbi Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors
    Alexander S Ho
    Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, Saint Louis, MO 63110, USA
    AJR Am J Roentgenol 188:1201-7. 2007
    ..and hepatic artery embolization (HAE) are accepted treatments of patients with hepatic metastasis from neuroendocrine tumors. Long-term outcome data are limited...
  11. ncbi Neuroendocrine tumors of the pancreas
    Florian Ehehalt
    Department for General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, University of Technology, Fetscherstrasse 74, Dresden, Germany
    Oncologist 14:456-67. 2009
    ..the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research...
  12. ncbi Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
    Simona Grozinsky-Glasberg
    Barts and the London School of Medicine, Centre for Endocrinology, University of London, London EC1M 6BQ, UK
    Endocr Relat Cancer 15:701-20. 2008
    ..The development of new SSA, new drug combination therapies and chimaeric molecules should further improve the clinical management of these patients, as should a more complete understanding of their mode of action...
  13. ncbi Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors
    Dana A Osborne
    Digestive Disorders Center, Tampa General Hospital, 1 Davis Island, Tampa, Florida 33601, USA
    Ann Surg Oncol 13:572-81. 2006
    ..exist regarding outcomes after resection versus embolic treatment of symptomatic metastatic carcinoid and neuroendocrine tumors. The purpose of this study was to determine whether cytoreduction provides any benefit over embolic ..
  14. ncbi Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
    ..To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers...
  15. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
    ....
  16. ncbi Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival
    Peter J Mazzaglia
    Rhode Island Hospital, Providence, RI, USA
    Surgery 142:10-9. 2007
    ..This study analyzes our 10-year experience and determines characteristics predictive of survival...
  17. ncbi Neuroendocrine neoplasms of the gut and pancreas: new insights
    Guido Rindi
    Institute of Pathology, Università Cattolica del Sacro Cuore Policlinico A Gemelli, Largo A Gemelli 8, I 00168 Rome, Italy
    Nat Rev Endocrinol 8:54-64. 2012
    ..Epidemiological data show a worldwide increase in the prevalence and incidence of gastroentero-pancreatic neuroendocrine tumors in the past few decades, which is probably due to improved methods of detection of these tumors...
  18. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    ..111)In-DTPA(0)]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs)...
  19. ncbi Neuroendocrine tumor epidemiology: contrasting Norway and North America
    Oyvind Hauso
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 113:2655-64. 2008
    ..Norway also holds a robust and detailed cancer registry: the Norwegian Registry of Cancer (NRC)...
  20. ncbi Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
    Martin B Niederle
    Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
    Endocr Relat Cancer 17:909-18. 2010
    ..7%) were grade 1, 31.2% grade 2 and 9.1% grade 3. NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated. G3 tumours are very rare...
  21. ncbi Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours
    Eva Tiensuu Janson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Acta Oncol 49:740-56. 2010
    ..The guidelines are meant to be useful in the daily practice for clinicians handling patients with neuroendocrine tumours...
  22. pmc Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
    Barbara Sennino
    Comprehensive Cancer Center, Department of Anatomy, University of California San Francisco UCSF, San Francisco, CA 94143 0452, USA
    Cancer Discov 2:270-87. 2012
    ..Treatment of pancreatic neuroendocrine tumors in RIP-Tag2 mice with a neutralizing anti-VEGF antibody reduced tumor burden but increased tumor hypoxia, ..
  23. ncbi Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
    Amy Moreno
    Department of Surgical Oncology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Endocr Relat Cancer 15:257-66. 2008
    ..was to determine the antitumor activity of rapamycin and octreotide as single agents and in combination in neuroendocrine tumors. In carcinoid cell lines BON-1 and NCI-H727, cell proliferation was significantly inhibited by rapamycin ..
  24. pmc Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
    Matthew H Kulke
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 29:934-43. 2011
    b>Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production of hormones and vasoactive peptides...
  25. ncbi Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    Standard, intravenous chemotherapy regimens for neuroendocrine tumors have been associated with limited response rates and significant toxicity...
  26. ncbi Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 36:147-56. 2006
    ..currently few treatment options exist for patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NET)...
  27. ncbi The diagnosis and medical management of advanced neuroendocrine tumors
    Gregory A Kaltsas
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    Endocr Rev 25:458-511. 2004
    b>Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular ..
  28. ncbi Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival
    Juan M Sarmiento
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Am Coll Surg 197:29-37. 2003
    Hepatic metastases from neuroendocrine tumors have a protracted natural history and are associated with endocrinopathies. Resection is indicated for symptom control...
  29. ncbi Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Davide Campana
    Department of Internal Medicine and Gastroenterology, University of Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    J Clin Oncol 25:1967-73. 2007
    We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) ..
  30. ncbi Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors
    Rudolf Arnold
    Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Philipps University, Marburg, Germany
    Clin Gastroenterol Hepatol 6:820-7. 2008
    The prognostic role of plasma chromogranin A in patients with neuroendocrine tumors is unclear...
  31. ncbi Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy
    Daniel Putzer
    Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
    J Nucl Med 50:1214-21. 2009
    ..We compared the diagnostic value of CT with that of the novel somatostatin analog (68)Ga-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) in the detection of such metastases...
  32. ncbi Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 10:451-8. 2003
    ..Currently, [(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide, [(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and [(90)Y-DOTA(0)]lanreotide can be used for this purpose...
  33. ncbi The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
    Andrea Frilling
    Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany
    Ann Surg 252:850-6. 2010
    To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET).
  34. ncbi The epidemiology of gastroenteropancreatic neuroendocrine tumors
    Ben Lawrence
    Gastrointestinal Pathobiology Research Group, Department of Surgery, Yale University School of Medicine, 310 Cedar Street, PO Box 208602, New Haven, CT 06520 8062, USA
    Endocrinol Metab Clin North Am 40:1-18, vii. 2011
    ..Overall, GEP-NET survival has improved over the past 3 decades, although the outcome for poorly differentiated tumors remains dismal...
  35. pmc Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Jolanta Kunikowska
    Nuclear Medicine Department, Medical University of Warsaw, ul Banacha 1 a, 02 097, Warsaw, Poland
    Eur J Nucl Med Mol Imaging 38:1788-97. 2011
    ..The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone...
  36. ncbi Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?
    H Scherubl
    Klinik für Gastroenterologie und GI Onkologie, Vivantes Klinikum Am Urban, Berlin, Germany
    Endoscopy 42:664-71. 2010
    Well differentiated neuroendocrine tumors (NETs) of the stomach (gastric carcinoid tumors) are observed more often, with a tenfold increase in the US in the last 30 - 35 years, and the prognosis has improved greatly in that time...
  37. ncbi Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography
    H Orlefors
    Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    J Clin Endocrinol Metab 90:3392-400. 2005
    b>Neuroendocrine tumors (NETs) can be small and situated almost anywhere throughout the body...
  38. ncbi Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers
    Linda Villard
    University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Clin Oncol 30:1100-6. 2012
    ..Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes...
  39. ncbi Small intestinal neuroendocrine tumors: prognostic factors and survival
    Deidi Strickland Bergestuen
    Department of Medicine, Section of Gastroenterology, Rikshospitalet University Hospital, Oslo, Norway
    Scand J Gastroenterol 44:1084-91. 2009
    Small intestinal neuroendocrine tumors (SI-NETs) make up 38% of gastroenteropancreatic neuroendocrine tumors...
  40. ncbi Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors
    Ulrich Frank Pape
    Department of Hepatology and Gastroenterology, Chariteé Campus Virchow Clinic, Berlin University of Medicine, Berlin, Germany
    Cancer 113:256-65. 2008
    b>Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system comprise a rare but challenging group of malignant neoplasms and occur at virtually any site of the GEP system...
  41. ncbi Gastrointestinal neuroendocrine tumors
    K E Oberg
    Department of Endocrine Oncology, University Hospital, SE 751 85 Uppsala, Sweden
    Ann Oncol 21:vii72-80. 2010
    Gastrointestinal neuroendocrine tumors (GI-NETs) are a genetically diverse group of malignancies that sometimes produce peptides causing characteristic hormonal syndromes...
  42. pmc Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
    N C Turner
    Department of Oncology, UCL Medical School, Royal Free Campus, London, UK
    Br J Cancer 102:1106-12. 2010
    ..The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen...
  43. ncbi Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory MedicineEuropean Institute of Oncology and National Cancer Institute, Milan, Italy
    Anticancer Res 30:4269-81. 2010
    Little is known about the dual role of RAS-association domain family 1 (RASSF1) gene at 3p21.3 in neuroendocrine tumors (NET) of the lung.
  44. ncbi Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?
    Vincenzo Mazzaferro
    Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Istituto Nazionale Tumori Fondazione IRCCS, Via Venezian 1, Milan 20133, Italy
    J Hepatol 47:460-6. 2007
  45. ncbi Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome
    Henning Jann
    Department of Hepatology and Gastroenterology, Charite, Campus Virchow Klinikum, University Medicine Berlin, Berlin, Germany
    Cancer 117:3332-41. 2011
    ..The purpose of this study was to test the efficacy of a proposal for TNM staging and grading for midgut and hindgut NETs...
  46. pmc Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer
    Teresa Chiaverotti
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Pathol 172:236-46. 2008
    ..Adenocarcinomas were not seen in our cohort. Thus, neuroendocrine carcinomas are the principal malignancy in this model and may develop from bipotential progenitor cells at an early stage of prostate tumorigenesis...
  47. ncbi Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 28:69-76. 2010
    ....
  48. ncbi Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors)
    In Seon Choi
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Mod Pathol 20:802-10. 2007
    b>Neuroendocrine tumors including carcinoid tumors and pancreatic endocrine tumors are uncommon, and the genetic alterations in these indolent tumors are not well characterized...
  49. pmc Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
    E Mitry
    Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 81:1351-5. 1999
    ..However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed...
  50. pmc Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
    T R Halfdanarson
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Ann Oncol 19:1727-33. 2008
    Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms that can present with symptoms of hormone overproduction. We evaluated the incidence, prognosis, and temporal trends of PNETs.
  51. ncbi Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
    R Garcia-Carbonero
    Department of Medical Oncology, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Sevilla
    Ann Oncol 21:1794-803. 2010
    b>Neuroendocrine tumors (NETs) are an unusual family of neoplasms with a wide and complex spectrum of clinical behavior...
  52. ncbi The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification
    Gunter Kloppel
    Department of General Pathology, University of Kiel, Kiel, Germany
    Ann N Y Acad Sci 1014:13-27. 2004
    ..In this review a classification of gastroenteropancreatic neuroendocrine tumors based on the WHO criteria is described. We also classify and comment on the most important tumor entities...
  53. ncbi Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival
    Frederike G I van Vilsteren
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:448-56. 2006
    ..In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients...
  54. ncbi Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT
    Vikas Prasad
    Department of Nuclear Medicine and Centre for PET CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany
    Eur J Nucl Med Mol Imaging 37:67-77. 2010
    ....
  55. ncbi Bronchopulmonary neuroendocrine tumors
    Bjorn I Gustafsson
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06520 8062, USA
    Cancer 113:5-21. 2008
    Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise approximately 20% of all lung cancers and represent a spectrum of tumors arising from neuroendocrine cells of the BP-epithelium...
  56. ncbi Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
    G Kaltsas
    Department of Endocrinology, St. Bartholomew's Hospital, London, United Kingdom EC1A 7BE
    J Clin Endocrinol Metab 86:895-902. 2001
    ..123)I]MIBG) and [(111)In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease...
  57. ncbi Pancreatic neuroendocrine tumors
    Elizabeth Batcher
    Division of Endocrinology and Metabolism, Harbor UCLA Medical Center, Torrance, California 90502, USA
    Endocr Res 36:35-43. 2011
    Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms representing <5% of all pancreatic malignancies with an estimated incidence of 1-1.5 cases/100,000. PNETs are broadly classified as either functional or nonfunctional...
  58. ncbi The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors
    Simon Schimmack
    Gastrointestinal Pathobiology Research Group, Department of Gastroenterological Surgery, Yale University School of Medicine, New Haven, CT, USA
    Langenbecks Arch Surg 396:273-98. 2011
    Recent data demonstrate that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased exponentially (overall ~500%) over the last three decades, thus refuting the erroneous concept of rarity...
  59. ncbi Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence
    Konstanze Miehle
    Department of Endocrinology, University of Leipzig, Germany
    J Clin Endocrinol Metab 89:3731-6. 2004
    ..This case underscores the pluripotency of neuroendocrine tumor cells and the importance of keeping in mind a possible shift in hormone production during tumor evolution and progression...
  60. pmc Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors
    Johannes Voortman
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:13040-5. 2010
    The goal of this study was to characterize and classify pulmonary neuroendocrine tumors based on array comparative genomic hybridization (aCGH)...
  61. ncbi Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma
    Tarik Belhocine
    Department of Nuclear Medicine, Jules Bordet Cancer Institute, Brussels, Belgium
    Oncol Rep 16:347-52. 2006
    ..It is concluded that whole-body 18FDG PET may be useful in the management of MCC patients. However, a normal 18FDG PET aspect cannot rule out MCC with low proliferative activity...
  62. pmc Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
    Elizabeth Allen
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, The University of California at San Francisco, San Francisco, California, USA
    Clin Cancer Res 17:5299-310. 2011
    Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking ..
  63. ncbi Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT
    Matthias Miederer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaningerstrasse 22, 81675, Munchen, Germany
    Eur J Nucl Med Mol Imaging 36:48-52. 2009
    ..g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptake value (SUV) of preoperative or prebiopsy (68)Ga-DOTATOC PET/CT...
  64. ncbi The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
    Saila Kauhanen
    Turku PET Center, Turku University Central Hospital, FIN 20521 Turku, Finland
    Endocr Relat Cancer 16:255-65. 2009
    ..positron emission tomography-computed tomography ([(18)F]DOPA PET-CT) in patients with neuroendocrine tumors (NETs). Eighty-two patients with suspected/known NET were imaged with PET(-CT) using [(18)F]DOPA...
  65. ncbi The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors
    Ben Lawrence
    Gastrointestinal Pathobiology Research Group, Department of Surgery, Yale University School of Medicine, 310 Cedar Street, PO Box 208602, New Haven, CT 06520 8062, USA
    Endocrinol Metab Clin North Am 40:111-34, viii. 2011
    ..useful general tumor biomarker available for use in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs)...
  66. pmc Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation
    Martin B Niederle
    Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University of Vienna, Währinger Gür, Austria
    Oncologist 16:602-13. 2011
    ..analyzed clinical investigation was to describe "unmasked" clinical symptoms and methods of diagnosis, treatment, and short-term follow-up of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) diagnosed during 1 year in Austria.
  67. ncbi Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting
    Jean Claude Reubi
    Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland
    Eur J Nucl Med Mol Imaging 30:781-93. 2003
    ..Finally, the data strongly encourage concomitant application of several radiopeptides to permit more efficient targeting of these tumours...
  68. ncbi Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy
    Kjell E Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Gastroenterology 139:742-53, 753.e1. 2010
    The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years...
  69. ncbi Human polyomaviruses and other human viruses in neuroendocrine tumors
    Markus Schmitt
    Research Program Infection and Cancer, German Cancer Research Center DKFZ, Im Neuenheimer Feld 242, Heidelberg, Germany
    Cancer Epidemiol Biomarkers Prev 20:1558-61. 2011
    ....
  70. ncbi ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival
    Birgit Guldhammer Skov
    Department of Pathology, Gentofte Hospital, DK 2900 Gentofte, Denmark
    J Thorac Oncol 5:453-9. 2010
    ..The associations of ERCC1 and Ki67, clinical features and survival in small cell lung carcinoma (SCLC), typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LCNEC) were determined...
  71. pmc Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors
    Tao Cui
    Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden
    PLoS ONE 5:e16010. 2010
    Small intestine neuroendocrine tumors (SI-NETs) belong to a rare group of cancers. Most patients have developed metastatic disease at the time of diagnosis, for which there is currently no cure...
  72. ncbi Peptide receptor therapies in neuroendocrine tumors
    L Bodei
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435 20141 Milan, Italy
    J Endocrinol Invest 32:360-9. 2009
    b>Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, able to produce bioactive amines and hormones. NETs tend to be slow growing and are often diagnosed when metastatic...
  73. ncbi Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
    Valentina Ambrosini
    Unità Operativa di Medicina Nucleare, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Padiglione 30, Via Massarenti 9, 40138, Bologna, Italy
    Eur J Nucl Med Mol Imaging 35:1431-8. 2008
    ..At present, there are no comparative studies investigating their role in NET...
  74. ncbi Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
    Cosimo Durante
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
    Endocr Relat Cancer 16:585-97. 2009
    ..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
  75. pmc Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
    ..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...
  76. ncbi Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery
    D Jaeck
    Centre de Chirurgie Viscerale et de Transplantation, Hopital de Hautepierre, 1 Avenue Moliere, 67098 Strasbourg Cedex, France
    World J Surg 25:689-92. 2001
    Liver metastases of neuroendocrine tumors are usually slow-growing, and cytoreductive hepatectomy can help reduce the effects of endocrinopathies and increase life expectancy and symptom-free survival...
  77. ncbi Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland
    Andreas Klaus Pfeifer
    Department of Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, Denmark
    Neuroendocrinology 93:189-96. 2011
    ..therapeutic options have highlighted the demand for new treatment modalities for patients with advanced neuroendocrine tumors (NET)...
  78. ncbi New treatment options for patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Curr Treat Options Oncol 12:136-48. 2011
    Well- to moderately differentiated neuroendocrine tumors (NET) are a heterogeneous group of malignancies for which a range of therapeutic options have been employed...
  79. ncbi 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors
    Tina Binderup
    Department of Clinical Physiology, University of Copenhagen, Copenhagen, Denmark
    Clin Cancer Res 16:978-85. 2010
    ..The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors...
  80. ncbi New strategies for advanced neuroendocrine tumors in the era of targeted therapy
    Mei Dong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1830-6. 2012
    ..Development of rational combinations may further improve therapeutic outcome. These successes and our improved understanding of the underlying molecular biology are likely to lead to further important advances on the horizon...
  81. ncbi Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review
    Gabriele Capurso
    Digestive and Liver Disease Unit, II School of Medicine, Sapienza University of Rome, Rome, Italy
    Neuroendocrinology 93:223-9. 2011
    ....
  82. ncbi Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum
    J Singer
    Medical Department III, University of Leipzig, Germany
    Exp Clin Endocrinol Diabetes 118:524-9. 2010
    ....
  83. ncbi Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases
    A E Siperstein
    Department of General Surgery/A80, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    World J Surg 25:693-6. 2001
    ..Radiofrequency thermal ablation is a relatively new modality that can be performed percutaneously or laparoscopically, and encouraging results have been obtained with it for treatment of neuroendocrine liver metastases...
  84. ncbi TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study
    G Rindi
    Institute of Anatomic Pathology, Universita Cattolica del Sacro Cuore, Histopathology and Cytodiagnosis Unit, Policlinico Gemelli, Largo A Gemelli, 8, Roma I 00168, Italy
    J Natl Cancer Inst 104:764-77. 2012
    ..This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms...
  85. ncbi Pancreatic neuroendocrine tumors: the impact of surgical resection on survival
    Joshua S Hill
    Department of Surgery, Surgical Outcomes Analysis and Research, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Cancer 115:741-51. 2009
    Although surgical resection is generally recommended for patients with localized pancreatic neuroendocrine tumors (PNETs), the impact of resection on overall survival is unknown...
  86. ncbi Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review
    R Arnold
    Department of Internal Medicine, Philipps University, Marburg, Germany
    Digestion 62:84-91. 2000
    ..Somatostatin and its long-acting analogues are effective in symptom control in patients with functionally active neuroendocrine GEP tumours. Several in vitro and in vivo reports suggest that they are also able to control tumour growth...
  87. pmc NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Pancreas 39:735-52. 2010
    Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs...
  88. ncbi Spatial segmentation of imaging mass spectrometry data with edge-preserving image denoising and clustering
    Theodore Alexandrov
    Center for Industrial Mathematics, ZeTeM, University of Bremen, 28334 Bremen, Germany
    J Proteome Res 9:6535-46. 2010
    ..Second, a section of a neuroendocrine tumor invading the small intestine was interpreted where the tumor area was discriminated and functionally similar regions were indicated...
  89. ncbi Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours
    A H G Davies
    Institute of Liver Studies, Carcinoid Clinic, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Eur J Cancer 42:477-84. 2006
    ..The EORTC QLQ-NET21 provides a site-specific module to supplement the QLQ-C30 for patients with neuroendocrine tumours...
  90. ncbi Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
    A Ahmed
    Basingstoke and North Hampshire Foundation Trust, Basingstoke, UK
    Endocr Relat Cancer 16:885-94. 2009
    ..For the first time, we have shown that Ki67 and resection of primary are independent predictors of survival for this group of patients...
  91. ncbi Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease
    Irvin M Modlin
    Gastrointestinal Pathobiology Research Group, Yale University School of Medicine, New Haven, CT, USA
    Ann Surg Oncol 17:2427-43. 2010
    b>Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., chromogranin A (CgA) and amines...
  92. ncbi Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
    Francesco Panzuto
    Department of Digestive and Liver Disease, University of La Sapienza, Roma, Italy
    Endocr Relat Cancer 12:1083-92. 2005
    ..5%. Pancreatic site, a poor degree of tumor cell differentiation and distant extra-hepatic metastases are the major negative prognostic factors...
  93. ncbi Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis
    Zofia Von Marschall
    Department of Hepatology, Gastroenterology, Endocrinology and Metabolism, Charite, Campus Virchow Klinikum, Humboldt University, Berlin, Germany
    J Natl Cancer Inst 95:437-48. 2003
    ....
  94. ncbi Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:9-15. 2003
    ..Because Lys75 produced serious hyperkalaemia, it is not suitable for clinical use. LysArg, however, is effective in offering renal protection in PRRT and is safe...
  95. ncbi Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
    I Buchmann
    Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 34:1617-26. 2007
    ..The aim of our study was to compare the value of (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations...
  96. ncbi Rare tumors of the colon and rectum: a national review
    Hakjung Kang
    Department of Surgery, Daehang Hospital, Seoul, South Korea
    Int J Colorectal Dis 22:183-9. 2007
    ..This population-based evaluation is the first comprehensive look at four rare histologic types of CRC, allowing comparisons with the more common adenocarcinoma for clinical and pathological features and survival rates...
  97. ncbi The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors
    Ursula Ploeckinger
    Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Neuroendocrinology 90:349-63. 2009
    Clinical experience with neuroendocrine tumors (NETs) is difficult to acquire because they are rare and heterogeneous. The impact of guidelines on the care for NETs is not known...
  98. ncbi Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors
    Dermot O'Toole
    Department of Clinical Medicine and Gastroenterology, St James s Hospital and Trinity College Dublin, James s Street, Dublin 8, Ireland
    Endocr Relat Cancer 17:847-56. 2010
    Response rates to cytotoxics in gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) vary; recent trials demonstrated lack of objective response rates in up to 70% of patients...
  99. ncbi Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG
    Irfan Kayani
    Institute of Nuclear Medicine, University College Hospital, London, UK
    Cancer 112:2447-55. 2008
    The aim was to assess the relevant distribution of the novel PET tracer (68)Ga-DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) and compare its performance with that of (..
  100. ncbi Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry
    Adele Caldarella
    Clinical and Descriptive Epidemiology Unit, Institute for Study and Cancer Prevention, Florence, Italy
    Pathol Oncol Res 17:759-63. 2011
    b>Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described...
  101. ncbi Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
    Mallika Singh
    Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Pathol 227:417-30. 2012
    ..Moreover, these data underscore the concept that drugs targeting VEGF ligands and receptors may affect tumour metastasis in a context-dependent manner and are mechanistically distinct from one another...

Research Grants63

  1. Transcriptional regulation of enteroendocrine cell differentiation by NeuroD
    Andrew B Leiter; Fiscal Year: 2013
    ..Activation of constitutive Wnt signaling in neurogenin 3 expressing cells induced intestinal neuroendocrine tumors whereas Wnt activation in NeuroD expressing cells did not, suggesting that NeuroD expression represents a ..
  2. Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology
    ALAN KEITH MEEKER; Fiscal Year: 2013
    ..mechanism was found to be utilized in 46% of the subtypes;with notable prevalence in sarcomas, pancreatic neuroendocrine tumors and certain tumors of the central nervous system...
  3. Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma
    DOMINIC JAMES SMIRAGLIA; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Neuroendocrine tumors of the pancreas are relatively rare but there remains considerable interest in these entities because of the complexity of the tumor spectrum and the uncertain histogenesis...
  4. Development of a kit based PET molecular imaging agent: edotreotide Ga 68 for so
    James F Kronauge; Fiscal Year: 2010
    ..Clinical studies have demonstrated PET imaging with edotreotide Ga 68 in thyroid disease, neuroendocrine tumors, gastrinomas, carcinoid, meningiomas, prostate cancer, thymoma, and non-small cell lung carcinoma...
  5. Molecular Pathogenesis of the Hamartoma Syndromes
    David J Kwiatkowski; Fiscal Year: 2013
    ..in the development of typical adult malignancies: TSC1 - bladder carcinoma;TSC2 - PEComas pancreatic neuroendocrine tumors, and bladder cancer;PTEN - many adult cancers, including breast, lung, and bladder cancer;and LKB1 - lung ..
  6. Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
    Edward L Schwartz; Fiscal Year: 2013
    ..pancreatic cancers, malignancies originating from neuroendocrine cells in the pancreas, called pancreatic neuroendocrine tumors (PNET), lack a desmoplastic fibroinflammatory capsule and are highly vascularized...
  7. Regulation and Function of Ascl1 in Neural Development
    Jane E Johnson; Fiscal Year: 2013
    ..In this respect, it is not surprising that Ascl1 expression is aberrantly present n neural and neuroendocrine tumors, and has also been identified as a key factor in directly reprogramming fibroblasts to neurons...
  8. REGULATION OF SODIUM CHANNELS IN EXCITABLE CELLS
    Gail Mandel; Fiscal Year: 2013
    ..Many of these genes encode signature proteins of neuroendocrine tumors and may be involved in other types of epithelial cancers as well...
  9. A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec
    James F Kronauge; Fiscal Year: 2012
    ..Clinical studies have demonstrated PET imaging with edotreotide Ga 68 in thyroid disease, neuroendocrine tumors, gastrinomas, carcinoid, meningiomas, prostate cancer, thymoma, non- small cell lung carcinoma and as a ..
  10. Biannual von Hippel Lindau Family Alliance Medical Meeting
    Eric Jonasch; Fiscal Year: 2011
    ..clear cell renal cell carcinomas (RCC), pheochromocytomas, pancreatic cysts and pancreatic neuroendocrine tumors. It is important to note that sporadic clear cell RCC also harbors a somatic VHL mutation in over 80 ..
  11. Image-guided Diagnosis and Therapy of Neuroendocrine Tumors
    M SUE O'DORISIO; Fiscal Year: 2013
    ..peptide receptor radio-therapy (PRRT) provides superior response rates in patients with neuroendocrine tumors (NETs) compared to any treatments currently available;yet, it is not available for patients in the United ..
  12. Integrins and Caspase 8 in Tumor Progression
    Dwayne G Stupack; Fiscal Year: 2013
    ..Its expression is frequently lost among aggressive neuroblastoma and other neuroendocrine tumors. This has prompted clinical strategies seeking to restore or amplify its expression...
  13. Dosimetry Guided Phase II of 90Y-DOTA-tyr3-Octreotide + Retinoic Acid in Kids
    M SUE SUE O apos DORISIO; Fiscal Year: 2010
    ..responses, 24% minimal responses, and 24% stable disease in children with brain tumors, neuroblastoma, and neuroendocrine tumors who had failed previous first and second line therapeutic options...
  14. Multipotential mesenchymal stem cell-like cells in pancreatic tumorigenesis
    Gabriele Bergers; Fiscal Year: 2013
    ..a p75NTR+/CD133+ population of multipotent mesenchymal stem-cell-like cells (MPMSC) in pancreatic neuroendocrine tumors that exhibit high self-renewal capacity and differentiate into endothelial, pericytes and probably other ..
  15. Regulation of somatostatin receptor signaling
    Agnes Schonbrunn; Fiscal Year: 2012
    ..therapeutic target for the SS analogs used to treat patients with pituitary and gastro-enteropancreatic neuroendocrine tumors in order to inhibit hormonal hyper-secretion and to reduce tumor growth...
  16. Reliable Human-Model Observers for Emission Tomography
    HOWARD CARL GIFFORD; Fiscal Year: 2013
    ..through observer studies with fluorine-18 deoxyglucose (FDG) whole-body PET and SPECT In-111 imaging of neuroendocrine tumors (NETs)...
  17. DOSIMETRY IN CHILDREN AND YOUNG ADULTS WITH NEUROBLASTOMA OR NEUROENDOCRINE TUMOR
    M SUE O DORISIO; Fiscal Year: 2009
    ..molecularly targeted therapy with 90Y-DOTA-tyr3-Octreotide has improved quality of life in patients with neuroendocrine tumors, but the dose is limited by toxicity to kidneys...
  18. Molecular and Genetic Analysis of Neuroendocrine Tumor Risk and Survival
    Matthew H Kulke; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The incidence of neuroendocrine tumors is increasing, and the annual prevalence of these malignancies is estimated to exceed 100,000 individuals in the United States...
  19. DIGITAL RESTORATION OF SPECT IMAGES FOR TUMOR DETECTION
    Michael A King; Fiscal Year: 2010
    ..The clinically significant procedures of single photon emission computed tomographic (SPECT) imaging for neuroendocrine tumors and for bone imaging of back-pain have been selected as the test-beds for our investigations...
  20. Astatine 211 & Radioiodine Labeled Octreotide Conjugates
    Michael Zalutsky; Fiscal Year: 2004
    ..that the concentratior of sst2 on human medulloblastoma is extremely high, even higher than on neuroendocrine tumors. Medulloblastoma is the most frequent central nervous system tumor in children with dismal outcome...
  21. DIAGNOSIS AND MANAGEMENT OF GUT/NEUROENDOCRINE TUMORS
    Aaron Vinik; Fiscal Year: 1993
    The major symptoms of neuroendocrine tumors are flushing and diarrhea. The precise pharmacology and pathophysiology of these symptoms remain obscure...
  22. RADIORECEPTOR GUIDED SURGERY OF NEURAL CREST TUMORS
    M O DORISIO; Fiscal Year: 2003
    ..Neural crest tumors derived from these precursors include neuroblastoma in children, neuroendocrine tumors of the gut and melanoma in adults...
  23. Autophagy in Pancreatic Neuroendocrine Tumor Growth and Metastasis
    Xuejun Jiang; Fiscal Year: 2013
    ..Pancreatic neuroendocrine tumors are the second most common malignancy of the pancreas...
  24. Regulation of Mouse Somatostatin Receptor Subtype 5 Gene
    WHITNEY WOODMANSEE; Fiscal Year: 2004
    ..regulation, but have long range clinical applications regarding the pathogenesis and treatment of neuroendocrine tumors. The somatostatin analog, octreotide, has been used to treat a variety of neuroendocrine tumors and ..
  25. CLINICAL PET AND LABORATORY STUDIES OF ADRENERGIC TUMORS
    Barry Shulkin; Fiscal Year: 2002
    ..The aim of this proposal is to evaluate the biodistribution of C-11epinephrine in patients with the neuroendocrine tumors neuroblastoma and pheochromocytoma, and to characterize the uptake and retention within tumors themselves...
  26. THYROID HORMONE REGULATION OF MOUSE SOMATOSTATIN TYPE 5
    WHITNEY WOODMANSEE; Fiscal Year: 2004
    ..regulation, but have long range clinical applications regarding the pathogenesis and treatment of neuroendocrine tumors. The somatostatin analog, octreotide, has been used to treat a variety of neuroendocrine tumors and ..
  27. Receptor Targeted, RGD-Linked, Cytotoxic Peptides
    Jack Erion; Fiscal Year: 2003
    Somatostatin receptors are expressed on a number of tumor types including, neuroendocrine tumors, small cell lung carcinoma, and breast cancer...
  28. Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals
    JAMES KRONAUGE; Fiscal Year: 2009
    ..The low specific activity iobenguane I 123 has been shown to be useful for the detection and staging of neuroendocrine tumors in adults and children and imaging neuronal activity in the heart...
  29. Developing Nanodosing of Iobenguane I 131 for Radiotherapy
    JAMES KRONAUGE; Fiscal Year: 2007
    ..and deliver doses of high specific activity iobenguane I 131 for radiotherapy in adults and children with neuroendocrine tumors. These are rare tumors with only about 800 cases a year in the US but with poor outcome and no approved ..
  30. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
    ..The radiopharmaceutical meta-iodobenzylguanidine (MIBG) has been used in the detection and therapy of neuroendocrine tumors, especially neuroblastoma and pheochromocytoma...
  31. Imaging of O6-Alkylguanine-DNA Alkyltransferase
    Ganesan Vaidyanathan; Fiscal Year: 2005
    ..In summary, this proposal seeks to determine whether the development of a suitable agent for the imaging of tumor AGT will facilitate chemotherapy planning, thereby improving the outcome of alkylator chemotherapy. ..
  32. Influence of Tumor Immunogenicity to Immunotherapy
    Jeffrey Norton; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  33. Phase II Clinical Trial Utilizing Lithium for Patients with Neuroendocrine Tumors
    Herbert Chen; Fiscal Year: 2008
    ..Besides surgery, there are limited curative and palliative treatments available to patients with metastatic NE tumors, emphasizing the need for development of other forms of therapy. [unreadable] [unreadable] [unreadable]..
  34. Signaling Pathways in Medullary Thyroid Cancer
    Herbert Chen; Fiscal Year: 2004
    ..abstract_text> ..
  35. Novel Signaling Targets in GI Neuroendocrine Tumors
    Herbert Chen; Fiscal Year: 2005
    ..The possibility that raf-l-mediated hormone suppression could be induced by a soluble factor would provide a plausible, therapeutic delivery method. ..
  36. FDG PET IMAGING OF COLON CARCINOMA RESPONSE TO THERAPY
    Michael Graham; Fiscal Year: 2001
    ....
  37. Regulating Neuroendocrine Phenotype in Cancer
    Herbert Chen; Fiscal Year: 2010
    ..Furthermore, these finding may permit development of components of raf-1 pathway as therapeutic targets in the treatment and palliation of NE tumors. ..
  38. Non-invasive beta-cell imaging using a Ga-68-labeled glucagone-like peptide-1 ana
    Martin Gotthardt; Fiscal Year: 2008
    ..Apart from proof-of-principle studies in healthy volunteers and diabetes type I and II patients, a dosimetric method will be established to simply and reliably quantify beta-cell mass by PET imaging. [unreadable] [unreadable]..
  39. Abnormality manipulation for tomographic imaging perception research
    Mark Madsen; Fiscal Year: 2009
    ..By making these abnormality manipulation tools available, this project will enable more and better research to reduce or eliminate diagnostic error, thereby improving public health. ..
  40. RADIORECEPTOR GUIDED SURGERY OF NEURAL CREST TUMORS
    M O DORISIO; Fiscal Year: 2002
    ..Neural crest tumors derived from these precursors include neuroblastoma in children, neuroendocrine tumors of the gut and melanoma in adults...
  41. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2003
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  42. A Novel Tool to Understand Insulin Production and Failure in Pancreatic beta-Cell
    Israel Hodish; Fiscal Year: 2008
    ..The model presented opens new avenues to the development and testing of potential therapeutic interventions that may ultimately help preserve insulin secretory function in humans with diabetes mellitus. [unreadable] [unreadable]..
  43. HUMAN GASTRIN-RELEASING PEPTIDE RECEPTOR GENE REGULATION
    Horst Weber; Fiscal Year: 2004
    ..Results will likely contribute to the general understanding of mechanisms of gene expression and signaling in cancer biology. ..
  44. Targeting RAF and VEGF Signaling in Thyroid Cancer
    Manisha Shah; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  45. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2006
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  46. TARGETS OF METASTATIC PANCREATIC CANCER
    Christine Iacobuzio Donahue; Fiscal Year: 2008
    ..abstract_text> ..
  47. Fish Oil Modulation of Tumor Inflammation
    NOCIF ESPAT; Fiscal Year: 2006
    ....
  48. Phase I Trial of 90Y Octreotide in Childhood Solid Tumor
    M O DORISIO; Fiscal Year: 2002
    ..The sst2 expression will be compared with tumor dosimetry and tumor response in order to determine if Real-time RT-PCR analysis of tumor receptor expression can predict response. ..
  49. Neurochemistry/physiology of proopiomelancortin neurons
    Malcolm Low; Fiscal Year: 2008
    ..The techniques involved are aggregation chimera formation and Cre recombinase mediated reactivation of POMC expression from a neuron-specific and reversibly silenced POMC allele. ..
  50. Preclin. model for prevention of NSCLC in former smokers
    HILDEGARD SCHULLER; Fiscal Year: 2006
    ....
  51. Cathartic-Free Dual-Energy CT Colonography
    Jeff Fidler; Fiscal Year: 2006
    ..The investigators have world-class expertise and resources in CT colonography, dual energy algorithms, and CT system calibrations. [unreadable] [unreadable]..
  52. HUMAN GASTRIN-RELEASING PEPTIDE RECEPTOR GENE REGULATION
    Horst Weber; Fiscal Year: 2004
    ..Due to its important relationship to mitogenic and other factors involved in carcinogenesis, these studies will greatly contribute to the general understanding of malignant transformation in gastrointestinal and other tissues. ..
  53. Tumor suppressor gene at 6q in adenoid cystic carcinoma
    Christopher Moskaluk; Fiscal Year: 2006
    ..Since AGO appears to have a smaller number of genetic changes than these other malignancies, it may serve as a simpler system to identify the 6q tumor suppressor gene. ..
  54. Imaging Thymidine Uptake During Treatment for Head and Neck Cancer
    Yusuf Menda; Fiscal Year: 2008
    ..The studies proposed here will refine and characterize a non-invasive imaging test that may allow treatment responses to be determined shortly after treatment has begun. [unreadable] [unreadable] [unreadable]..
  55. DIET AND DURATION OF CERVICAL HPV INFECTION
    MARC GOODMAN; Fiscal Year: 2009
    ....
  56. Operant Responding in Opioid-Deficient Mice
    Malcolm Low; Fiscal Year: 2004
    ..abstract_text> ..
  57. A NEURAL TRANSCRIPTION FACTOR IN LUNG CANCER EVOLUTION
    Douglas Ball; Fiscal Year: 2006
    ..The proposed studies should provide novel insights in SCLC biology and a firm basis for determining whether hASH1, and hASHl-regulated growth mechanisms, should be intensively pursued as therapeutic targets for SCLC. ..
  58. Transcription Factors in Neuroendocrine Differentiation
    Michael Lan; Fiscal Year: 2009
    ..Results from this study should help us to define the interplay between the IA-1 zinc-finger transcription factor and other neuroendocrine-specific transcription factors in pancreatic endocrine and neuronal development. ..
  59. NNK, Beta-Adrenergic AA Release and Lung Cancer
    HILDEGARD SCHULLER; Fiscal Year: 2005
    ..2. To determine which products of the AA cascade are formed in untreated cells and in response to NNK, which of these products stimulate DNA synthesis, and what downstream effectors are activated by these products. ..
  60. Academic Public Private Partnership Program
    M O DORISIO; Fiscal Year: 2004
    Research needs on which the proposed Academic Public Private Partnership Program (AP4) center will focus: Neuroendocrine tumors in adults arise from the neural crest and include carcinoid, multiple neuroendocrine neoplasias, ..
  61. Hepatitis Virus, Alcohol Exposure and Oxidative Stress
    Manal Hassan; Fiscal Year: 2002
    ..Serum Se, GPx activity, lipid peroxides and oxidative DNA damage will be measured in relation to HCV and alcohol intake history. ..